Shore Capital Reiterates Buy Rating for GSK (LON:GSK)

Shore Capital reissued their buy rating on shares of GSK (LON:GSK - Free Report) in a research note published on Wednesday, MarketBeat Ratings reports.

Several other research analysts also recently commented on the company. Deutsche Bank Aktiengesellschaft restated a buy rating and issued a GBX 1,950 ($24.49) target price on shares of GSK in a research note on Wednesday, April 17th. Barclays restated an equal weight rating and issued a GBX 1,725 ($21.67) price objective on shares of GSK in a research report on Monday, April 8th. Finally, Berenberg Bank upped their target price on shares of GSK from GBX 1,650 ($20.73) to GBX 1,820 ($22.86) and gave the stock a buy rating in a report on Wednesday, February 14th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of Hold and a consensus target price of GBX 1,630.63 ($20.48).

GSK Stock Performance

Shares of GSK stock traded up GBX 32 ($0.40) during trading hours on Wednesday, reaching GBX 1,705 ($21.42). The company had a trading volume of 5,228,820 shares, compared to its average volume of 6,879,913. The firm has a market cap of £69.73 billion, a PE ratio of 1,420.83, a price-to-earnings-growth ratio of 1.12 and a beta of 0.27. GSK has a one year low of GBX 1,302.60 ($16.36) and a one year high of GBX 1,719.80 ($21.60). The company has a debt-to-equity ratio of 140.82, a current ratio of 0.88 and a quick ratio of 0.73. The business has a fifty day simple moving average of GBX 1,660.86 and a 200 day simple moving average of GBX 1,555.08.

GSK Cuts Dividend

The business also recently disclosed a dividend, which will be paid on Thursday, July 11th. Stockholders of record on Thursday, May 16th will be given a dividend of GBX 15 ($0.19) per share. This represents a dividend yield of 0.9%. The ex-dividend date is Thursday, May 16th. GSK's dividend payout ratio (DPR) is currently 5,333.33%.

Insider Buying and Selling

In other news, insider Julie Brown purchased 19,360 shares of the stock in a transaction on Thursday, February 1st. The shares were acquired at an average price of GBX 1,583 ($19.88) per share, for a total transaction of £306,468.80 ($384,962.69). In other news, insider Julie Brown bought 19,360 shares of the business's stock in a transaction on Thursday, February 1st. The stock was acquired at an average price of GBX 1,583 ($19.88) per share, with a total value of £306,468.80 ($384,962.69). Also, insider Emma Walmsley sold 139,792 shares of the company's stock in a transaction on Friday, February 16th. The shares were sold at an average price of GBX 1,658 ($20.83), for a total transaction of £2,317,751.36 ($2,911,382.19). Over the last ninety days, insiders purchased 19,802 shares of company stock worth $31,381,484. Corporate insiders own 1.77% of the company's stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.